2025 United States Adenovirus Vaccine Market Revenue Opportunities Report
Description
The 2025 United States Adenovirus Vaccine Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Adenovirus Vaccine Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively engaged in the Adenovirus Vaccine Market in the United States are Teva Pharmaceuticals, Barr Laboratories (a subsidiary of Teva), PaxVax, Inc., and Johnson & Johnson. Teva Pharmaceuticals, including its subsidiary Barr Labs, currently supplies the widely used oral adenovirus Type 4 and Type 7 vaccines primarily for U.S. military personnel, with Barr holding contracts awarded by the Defense Logistics Agency for vaccine production through at least 2019. PaxVax was selected as a contractor for development of a modernized adenovirus vaccine version under U.S. government programs aiming to refresh supply and domestic production of vaccine materials previously sourced internationally. Johnson & Johnson, through its Janssen Pharmaceuticals, utilizes the AdVac adenovirus vector platform for its COVID-19 vaccine, reflecting advanced adenovirus-based vaccine technology and significant U.S. market activity.
These companies dominate adenovirus vaccine supply chains, especially for military and pandemic applications. Teva and Barr focus on oral live vaccines preventing respiratory illness in military recruits, while PaxVax develops next-generation formulations aiming for safer, domestic virus material production. Johnson & Johnson leverages adenovirus vectors in broader infectious disease vaccines, including COVID-19, indicating diversification in vaccine technology. This landscape reflects strong U.S. government investment and collaboration with industry to maintain vaccine availability and innovate adenovirus vaccine platforms.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Adenovirus Vaccine Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively engaged in the Adenovirus Vaccine Market in the United States are Teva Pharmaceuticals, Barr Laboratories (a subsidiary of Teva), PaxVax, Inc., and Johnson & Johnson. Teva Pharmaceuticals, including its subsidiary Barr Labs, currently supplies the widely used oral adenovirus Type 4 and Type 7 vaccines primarily for U.S. military personnel, with Barr holding contracts awarded by the Defense Logistics Agency for vaccine production through at least 2019. PaxVax was selected as a contractor for development of a modernized adenovirus vaccine version under U.S. government programs aiming to refresh supply and domestic production of vaccine materials previously sourced internationally. Johnson & Johnson, through its Janssen Pharmaceuticals, utilizes the AdVac adenovirus vector platform for its COVID-19 vaccine, reflecting advanced adenovirus-based vaccine technology and significant U.S. market activity.
These companies dominate adenovirus vaccine supply chains, especially for military and pandemic applications. Teva and Barr focus on oral live vaccines preventing respiratory illness in military recruits, while PaxVax develops next-generation formulations aiming for safer, domestic virus material production. Johnson & Johnson leverages adenovirus vectors in broader infectious disease vaccines, including COVID-19, indicating diversification in vaccine technology. This landscape reflects strong U.S. government investment and collaboration with industry to maintain vaccine availability and innovate adenovirus vaccine platforms.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
